A cartoon image shows an open laptop with a video call screen. The image shows 7 cartoon people in the video call in various states of speaking or listening.
Participant Spotlight
Read more
TrialNet Launches Community Advisory Board to Advance T1D Research
TrialNet has created a Community Advisory Board (CAB) to amplify the voices of people impacted by type 1 diabetes (T1D) in our research. As representatives of the T1D community, CAB members have the opportunity to influence TrialNet’s research, ensuring it provides the best possible experience for participants.
Image of intestines with a cropped circle showing a close up view of microrganisms in the microbiome. There is also another cropped circle with a magnifying glass examining data. TrialNet logo is in the top left corner.
Research Spotlight
Read more
Exploring the fascinating connection between the gut microbiome and immune therapy
While conducting research in his lab at Yale University, TrialNet Chair Kevan Herold, MD, discovered an interesting outcome. Mouse models (mice genetically modified to mimic a human condition) treated with multiple antibiotics did not respond to the immune therapy teplizumab, the only FDA-approved treatment to delay the onset of type 1 diabetes (T1D).
Lisa Gier in the foreground wearing a Camp Hodia shirt with a lake and snow-capped mountain in the background
Media Release
Read more
TrialNet Partner Spotlight: Diabetes Education & Camping Association Executive Director Lisa Gier
From camper to director of the largest camping association serving people with diabetes
When Lisa Gier attended her first diabetes camp at Camp Hodia (a mix of Idaho and diabetes) at age 10, she had no idea she would build an amazing career in camping.
Sign up here to join our mailing list for the latest updates on important T1D research and events, straight to your inbox. You can also find us on Facebook @DiabetesTrialNet.
